Kathleen is a courtroom litigator and former co-chair of the firm's global life sciences industry group. For more than 25 years, she has enjoyed an extensive civil litigation career through representation of diverse business entities such as consumer finance and financial services providers, communications providers, pharmaceutical and medical device companies, healthcare companies, and entertainment facilities involved in complex disputes. Kathleen also provides counsel to corporate policyholders in a variety of insurance first- and third-party coverage-related disputes and litigation, including environmental, property, products liability, professional liability, business interruption, and directors and officers. She also litigates extra-contractual disputes and frequently provides insurance-related due diligence counsel in corporate transactions.
Her experience includes, but has not been limited to, litigating business and consumer credit disputes, class actions, civil RICO, pharmaceutical/medical device/consumer product diversion, unfair and deceptive trade practices, bad faith, intellectual property, products liability, FCRA, TILA, FCBA, and FDCPA. Clients frequently call on her to handle matters pending in jurisdictions where juries are hostile to corporate defendants, and she has represented clients in Arkansas, Mississippi, Florida, North Carolina, Kentucky, Nebraska, New York, New Jersey, South Carolina, Texas, California and Virginia. Upon graduation from law school, she served a one-year clerkship with the Honorable Melvin P. Antell, Presiding Judge of the Superior Court of New Jersey, Appellate Division. Kathleen has also served as an adjunct professor for law school legal research and writing classes.
In 2010, Kathleen received a healthcare compliance certification.
Kathleen is co-editor of the FDA Life blog which covers news and trends impacting the FDA and life science industry. Kathleen advises clients on pharmaceutical product diversion and is closely monitoring FDA’s new track-and-trace requirements under the Drug Supply Chain Security Act. She is also closely monitoring the CFPB’s regulatory developments and enforcement proceedings affecting consumer finance and how they will impact the firm’s credit card issuers.
